丽珠肠乐及莫沙必利治疗慢加急性亚急性肝衰竭疗效观察  

Observation on curative effect of live Bifidobacterium preparation and mosapride citrate dispersible tablets in fouty-two cases of actute-on-chronic liver failure

作　　者：李建阳[1] 刘福文[1] 华伟[1] 赵尚知[1] 

机构地区：[1]蓬安县人民医院,四川蓬安637800

出　　处：《中国微生态学杂志》2009年第5期456-457,共2页Chinese Journal of Microecology

摘　　要：目的观察丽珠肠乐及莫沙必利治疗慢加急性(亚急性)肝衰竭临床疗效。方法将2003年1月至2007年12月间住院的慢加急性(亚急性)肝衰竭患者随机分为治疗组和对照组,对照组仅给予内科综合治疗,治疗组在此基础上加用丽珠肠乐及莫沙必利口服治疗,疗程1月。结果治疗组有效率(79%)优于对照组(43%),治疗组治疗后出血、感染、肝性脑病、肝肾综合征、腹水并发症少于对照组。结论丽珠肠乐及莫沙必利治疗慢加急性(亚急性)肝衰竭临床疗效显著,预后改善明显。Objective To observe clinical effect of Live Bifidobacterium Preparation and Mosapride Citrate Dispersible Tablets on actute-on-ehronic liver failure. Method Cases of actute-on-ehronic liver failure from Jan. 2003 to Dee. 2007 were randomly divided into treatment group treated by comprehensive physical treatment combined with Live Bifidobacterium Preparation and Mosapfide Citrate Dispersible Tablets, and control group treated by comprehensive physical treatment for one month. Result The effective rate of treatment group was 79%, which was significantly higher than that of control group. The incidence of complication in treatment group such as hemorrhage, infection, hepatic encephalopathy and hepatorenal syndrome was significantly lower than that of control group. Conclusion The curative effect of Live Bifidobac- terium Preparation and Mosapride Citrate Dispersible Tablets on actute-on-chronic liver failure is clinically significant.

关 键 词：丽珠肠乐 莫沙必利 慢加急性(亚急性)肝衰竭 疗效 

分 类 号：R575.3[医药卫生—消化系统]